2025-05-16 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, presented in English with simple numerical summaries and analysis.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and provides health solutions through prescription medicines, vaccines, biologic therapies, and animal health products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -0.94%
*   **VOO Cumulative Return:** 81.82%
*   **Divergence:**
    *   **Current Divergence:** -82.8%
    *   **Relative Divergence:** 0.0%

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period examined. The current divergence is substantial, placing it at the very bottom of its historical divergence range. The Relative Divergence of 0.0 indicates it is at the lowest end of its historical underperformance relative to the VOO.

### Alpha, Beta Analysis

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 5.0%   | 58.4%  | -24.0%  | 0.0    | 108.3  |
| 2016-2018  | 42.0%  | 66.6%  | 24.0%   | 0.1    | 151.6  |
| 2017-2019  | 40.0%  | 66.6%  | 11.0%   | 0.2    | 185.4  |
| 2018-2020  | 19.0%  | 66.6%  | -6.0%   | 0.4    | 172.0  |
| 2019-2021  | -1.0%  | 65.6%  | -55.0%  | 0.5    | 175.0  |
| 2020-2022  | 13.0%  | 69.3%  | 7.0%    | 0.5    | 261.5  |
| 2021-2023  | 35.0%  | 69.3%  | 19.0%   | 0.3    | 264.2  |
| 2022-2024  | -6.0%  | 69.3%  | -23.0%  | 0.3    | 247.6  |
| 2023-2025  | -54.0% | 73.5%  | -83.0%  | 0.7    | 186.7  |

**Analysis:**

*   **CAGR & MDD:** The CAGR (Compound Annual Growth Rate) varies significantly across different periods, with a steep decline in the most recent period (2023-2025). Maximum Drawdown (MDD) remains high, indicating significant volatility.
*   **Alpha:** Alpha has been generally negative in recent periods, suggesting underperformance relative to its benchmark. The most recent period shows a very negative Alpha of -83.0%.
*   **Beta:** Beta values are relatively low, indicating lower sensitivity to market movements. However, the recent Beta has increased to 0.7, suggesting a slightly stronger correlation with the market.
*   **Capitalization (Cap):** The market capitalization has fluctuated over time but shows a general decline in the most recent period.

### 2. Recent Price Action

*   **Current Price:** 74.375
*   **Last Market Change:** Price increased by 1.23 (from 73.47 to 74.375)
*   **5-day Moving Average:** 77.509
*   **20-day Moving Average:** 79.9977
*   **60-day Moving Average:** 85.8655

**Analysis:** The stock price is below all three moving averages, suggesting a short-term and medium-term downtrend. The recent price increase, as indicated by the "Last Market Change," might be a slight rebound, but it's still below the moving averages.

### 3. Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.35 (Low Risk)
*   **RSI:** 41.72 (Approaching Oversold)
*   **PPO:** -0.3996 (Negative Momentum)
*   **Recent Relative Divergence Change (20-day):** -12.5 (Short-term Downtrend)
*   **Expected Return:** -1098.4% (Significant Underperformance vs. S&P 500)

**Analysis:**

*   The MRI suggests a low-risk environment, which is counterintuitive given the other negative indicators.
*   The RSI is approaching the oversold level, which could indicate a potential buying opportunity, but it is not yet at a level to be considered as such.
*   The negative PPO confirms the downward momentum.
*   The significant negative expected return suggests that, based on the model used, MRK is projected to significantly underperform the S&P 500 over the long term (2+ years) if investment starts from the current point.
*   Given the price increase ('price': 74.375, 'previousClose': 73.47, 'change': 1.23), the stock experienced a slight rebound.

### 4. Recent News & Significant Events

*   **[2025-05-14]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-13]:** Analyst discussions on performance and outlook.
*   **[2025-05-15]:** Notable stock volatility influenced by recent news.
*   **[2025-05-16]:** Market experts highlighting risks and opportunities.

**Analysis:** The news suggests recent activity and volatility surrounding MRK, requiring careful monitoring of company announcements and market reactions.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2024-05-03 | 1.88 | 15.78 B$   |
| 2025-05-02 | 1.88 | 15.78 B$   |

**Analysis:** The EPS and revenue figures show fluctuation. Revenue appears relatively stable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-03-31 | $48.34B    | 10.51% |
| 2024-12-31 | $46.31B    | 8.08%  |
| 2024-09-30 | $44.50B    | 7.09%  |
| 2024-06-30 | $43.58B    | 12.52% |
| 2024-03-31 | $40.36B    | 11.80% |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable over the past five quarters, with profit margins consistently high.
*   **Capital and Profitability:** Equity has been increasing, which is generally positive, but ROE has fluctuated.

### 7. Overall Summary

MRK is currently exhibiting several concerning indicators:

*   **Significant Underperformance:**  Substantially lagging the S&P 500.
*   **Negative Alpha:** Consistently underperforming its benchmark.
*   **Downtrend:**  Price below key moving averages.
*   **Negative Expected Return:** Model predicting significant long-term underperformance vs. S&P 500.

While the MRI suggests a low-risk environment, the overall picture points towards caution. The recent news indicating volatility and significant events further reinforces the need for careful monitoring of the stock. The financials show good profitability and growing equity, but this does not seem to translate into stock performance.  Investors should carefully consider these factors before making any investment decisions regarding MRK.
